Amyloid-β 1-42 levels are modified by apolipoprotein e ε4 in creutzfeldt-jakob disease in a similar manner as in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 23, Issue 4, 2011, Pages 717-726

  Varges, Daniela ^a   Jung, Klaus ^a   Gawinecka, Joanna ^a   Heinemann, Uta ^a   Schmitz, Matthias ^a   Von Ahsen, Nicolas ^a   Krasnianski, Anna ^a   Zerr, Inga ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Alzheimer's disease; amyloid ; apolipoprotein E; codon 129 genotype; Creutzfeldt Jakob disease; dementia; prion; tau

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; ENOLASE; PROTEIN 14 3 3; PROTEIN S 100;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DISEASE SEVERITY; FEMALE; GENE FREQUENCY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CELL; PRIORITY JOURNAL; RISK FACTOR;

EID: 79953289334     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101527     Document Type: Article

References (60)

1. Alpérovitch A, Zerr I, Pocchiari M, Mitrova E, de Pedro Cuesta J, Hegyi I, Collins S, Kretzschmar H, van Duijn C, Will RG (1999) Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 353, 1673-1674. (Pubitemid 29224526)
2. Del Bo R, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, Galimberti G, Galbiati S, Virgilio R, Galimberti D, Scarpini E, Bresolin N, Comi GP (2006) Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging 27, 770.e1-770.e5.
3. Golanska E, Hulas-Bigoszewska K, Sieruta M, Zawlik I, Witusik M, Gresner SM, Sobow T, Styczynska M, Peplonska B, Barcikowska M, Liberski PP, Corder EH (2009) Earlier onset of Alzheimer's disease: risk polymorphisms within PRNP, PRND, CYP46, and APOE genes. J Alzheimers Dis 17, 359-368.
4. Gacia M, Safranow K, Styczyńska M, Jakubowska K, Pepłońska B, Chodakowska-Zebrowska M, Przekop I, Słowik A, Golańska E, Hułas-Bigoszewska K, Chlubek D, Religa D, Zekanowski C, Barcikowska M (2006) Prion protein gene M129 allele is a risk factor for Alzheimer's disease. J Neural Transm113, 1747-1751. (Pubitemid 44657670)
5. Utermann G, Steinmetz A, Weber W (1982) Genetic control of human apolipoprotein E polymorphism:comparison of one-and two-dimensional analysis. Hum Genet 60, 344-351. (Pubitemid 12096392)
6. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ (1993) Association of apolipoprotein E allele epsilon 4 with late onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472. (Pubitemid 23230526)
7. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55, 937-945. (Pubitemid 28335112)
8. Davidson Y, Gibbons L, Purandare N, Byrne J, Hardicre J, Wren J, Payton A, Pendleton N, Horan M, Burns A, Mann DM (2006) Apolipoprotein E epsilon4 allele frequency in vascular dementia. Dement Geriatr Cogn Disord 22, 15-19.
9. Amouyel P, Vidal O, Launay JM, Laplanche JL (1994) The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. The French Research Group on Epidemiology of Human Spongiform Encephalopathies. Lancet 344, 1315-1318. (Pubitemid 24343194)
10. Van Everbroeck B, Croes EA, Pals P, Dermaut B, Jansen G, van Duijn CM, Cruts M, Van Broeckhoven C, Martin JJ, Cras P (2001) Influence of the prion protein and the apolipopro-tein E genotype on the Creutzfeldt-Jakob Disease phenotype. Neurosci Lett 313, 69-72. (Pubitemid 32973897)
11. Nakagawa Y, Kitamoto T, Furukawa H, Ogomori K, Tateishi J (1995) Allelic variation of apolipoprotein E in Japanese spo-radic Creutzfeldt-Jakob disease patients. Neurosci Lett 187, 209-211. ISSN: 0304-3940.
12. Salvatore M, Seeber AC, Nacmias B, Petraroli R, D'Alessandro M, Sorbi S, Pocchiari M (1995) Apolipoprotein E in sporadic and familial Creutzfeldt-Jakob disease. Neurosci Lett 199, 95-98.
13. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM (2004) Cere-brospinal fluid ß-amyloid 1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of ApoE E4 allele. Biol Psychiatry 56, 670-676. (Pubitemid 39446849)
14. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP (2007) No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain 130, 2320-2326. (Pubitemid 47327622)
15. Golombowski S, Müller-Spahn F, Romig H, Mendla K, Hock C (1997) Dependence of cerebrospinal fluid tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci Lett 225, 213-215. (Pubitemid 27191633)
16. Tapiola T, Pirttilä T, Mehta PD, Alafuzofff I, Lehtovirta M, Soininen H (2000) Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 21, 735-740.
17. 1-42) and tau in CSF, a multicenter study. Neurology 52, 1555-1562. (Pubitemid 29220627)
18. Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K (2008) CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. Neurosci Lett 440, 145-149.
19. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K (2004) APOE E4 allele is associated with reduced cere-brospinal fluid levels of Aß42. Neurology 62, 2116-2118. (Pubitemid 38738236)
20. Gmitterová K, Heinemann U, Bodemer M, Krasnianski A, Meissner B, Kretzschmar HA, Zerr I (2009) 14-3-3 CSF levels in sporadic Creutzfeldt-Jakob disease differ across molecular subtypes. Neurobiol Aging 30, 1842-1850.
21. Sanchez-Juan P, Sanchez-Valle R, Green A, Ladogana A, Cuadrado-Corrales N, Mitrova E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Krasnianski A, Equestre M, Slivarichova D, Saiz A, Calero M, Pocchiari M, Knight R, van Dujin CM, Zerr I (2007) Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis. J Neurol 254, 901-906. (Pubitemid 47222312)
22. WHO (1998) Human transmissible spongiform encephalo-pathies. Wkly Epidemiol Rec 47, 361-365.
23. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RSG, Bernheimer H, Cardone F, Delasnerie-Lauprêtre N, Cuadrado Corrales N, Ladogana A, Fletcher A, Bodemer M, Awan T, Ruiz Bremón A, Budka H, Laplanche JL, Will RG, Poser S (2000) Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 55, 811-815.
24. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie DA, Smith P, Varges D, Heinemann U, Meissner B, Roberts H, Brandel JP, Van Dujin CM, Pocchiari M, Begue P, Cras P, Will RG, Sanchez-Juan P (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 132, 2659-2668.
25. Riemenschneider M, Diehl J, Müller U, Forstl H, Kurz A (2002) Apolipoprotein E polymorphism in German patients with frontotemporal degeneration. J Neurol Neurosurg Psychiatry 72, 639-641. (Pubitemid 34462820)
26. Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang J (2006) Effect of sample collection tubes on cere-brospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem 52, 332-334. (Pubitemid 43185505)
27. Schoonenboom NSM, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, Scheltens P, Blankenstein MA (2005) Effects of processing and storage conditions on amy-loid ß (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 51, 189-195. (Pubitemid 40024030)
28. Mollenhauer B, Trenkwalder C, von Ahsen N, Bibl M, Steinacker P, Brechlin P, Schindehuette J, Poser S, Wiltfang J, Otto M (2006) Beta-amyloid 1-42 and tau-protein in cere-brospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Disord 22, 200-208. (Pubitemid 44310515)
29. Windl O, Giese A, Schulz-Schaeffer W, Zerr I, Skworc K, Arendt S, Oberdieck C, Bodemer M, Poser S, Kretzschmar HA (1999) Molecular genetics of human prion diseases in Germany. Hum Genet 105, 244-252. (Pubitemid 29440667)
30. Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J (1996) Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 53, 913-920. (Pubitemid 26301703)
31. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
32. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM (1991) The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
33. Lamb H, Christie J, Singleton AB, Leake A, Perry RH, Ince PG, McKeith IG, Melton LM, Edwardson JA, Morris CM (1998) Apolipoprotein E and alpha-1 antichymotrypsin poly-morphism genotyping in Alzheimer's disease and in dementia with Lewy bodies. Distinctions between diseases. Neurology 50, 388-391.
34. Ohm TG, Scharnagl H, März W, BohlJ (1999) Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathol 98, 273-280. (Pubitemid 29396859)
35. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L, Goldgaber D, Manwaring MG, Szymanski MH, McCown N (1993) Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 342, 710-711. (Pubitemid 23279765)
36. Pickering-Brown SM, Mann DM, Owen F, Ironside JW, de Silva R, Roberts DA, Balderson DJ, Cooper PN (1995) Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease. Neurosci-Lett 187, 127-129.
37. Krasnianski A, Von Ahsen N, Heinemann U, Meissner B, Schulz-Schaeffer WJ, Kretzschmar HA, Armstrong VW, Zerr I (2009) Increased frequency of positive family history of dementia in sporadic CJD. Neurobiol Aging 30, 615-621.
38. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schröter A, Ratzka P, Cepek L, Zerr I, Steinacker P, Windl O, Kornhuber J, Kretzschmar HA, Poser S, Wiltfang J (2000) Decreased beta-amyloid1-42in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54, 1099-1102. (Pubitemid 30151852)
39. Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, Mollenhauer B, Buerger K, Hampel H, Paul S, Neumann M, Maler M, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Otto M (2003) Beta-amyloid peptides in cere-brospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 54, 263-267. (Pubitemid 36909629)
40. Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H (2008) Increased CSF BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 131, 1252-1258.
41. Andersson C, Blennow K, Johansson SE, Almkvist O, Engfeldt P, Lindau M, Eriksdotter-Jönhagen M (2007) Differential CSF biomarker levels in APOE-epsilon4-positive and-negative patients with memory impairment. Dement Geriatr Cogn Disord 23, 87-95. (Pubitemid 46105699)
42. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR Jr; Alzheimer's Disease Neuroimaging Initiative (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67, 308-316.
43. Glodzik-SobanskaL, PirragliaE, Brys M, de Santi S, Mosconi L, Rich KE, Switalski R, Saint Louis L, Sadowski MJ, Martiniuk F, Mehta P, Pratico' D, Zinkowski RP, Blennow K, Leon MJ (2009) The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging 30, 672-681.
44. Tamgüney G, Giles K, Glidden DV, Lessard P, Wille H, Tremblay P, Groth DF, Yehiely F, Korth C, Moore RC, Tatzelt J, Rubinstein E, Boucheix C, Yang X, Stanley P, Lisanti MP, Dwek RA, Rudd PM, Moskovitz J, Epstein CJ, Cruz TD, Kuziel WA, Maeda N, Sap J, Ashe KH, Carlson GA, Tesseur 1, Wyss-Coray T, Mucke L, Weisgraber KH, Mahley RW, Cohen FE, Prusiner SB (2008) Genes contributing to prion pathogenesis. J Gen Virol 89, 1777-1788.
45. Baldeiras IE, Ribeiro MH, Pacheco P, Machado A, Santana I, Cunha L, Oliveira CR (2009) Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients. J Neurol 256, 1540-1550.
46. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302,385-393.
47. Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko DR (2006) Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 63, 936-939. (Pubitemid 44036292)
48. Liberski PP (2004) Amyloid plaques in transmissible spongi-form encephalopathies (prion diseases). Folia Neuropathol 42, 109-119.
49. Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I (2008) Quantitative anal-ysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis 14, 17-25. (Pubitemid 352039015)
50. Castellani RJ, Perry G, Smith MA (2004) Prion disease and Alzheimer's disease: pathogenic overlap. Acta Neurobiol Exp 64, 11-17. (Pubitemid 38453802)
51. Gunther EC, Strittmatter SM (2010)Beta-amyloidoligomers and cellular prion protein in Alzheimer's disease. J Mol Med 88, 331-338.
52. Reiniger L, Lukic A, Linehan J, Rudge P, Collinge J, Mead S, Brandner S (2010) Tau, prions and Abeta: the triad of neurodegeneration. Acta Neuropathol [Epub ahead of print].
53. Schwarze-Eicker K, Keyvani K, Görtz N, Westaway D, Sachser N, Paulus W (2005) Prion protein (PrPc) promotes beta-amyloid plaque formation. Neurobiol Aging 26, 1177-1182. (Pubitemid 40726010)
54. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-1132.
55. Voigtländer T, Klöppel S, Birner P, Jarius C, Flicker H, Verghese-Nikolakaki S, Sklaviadis T, Guentchev M, Budka H (2001) Marked increase of neuronal prion protein immunore-activity in Alzheimer's disease and human prion diseases. Acta Neuropathol 101, 417-423. (Pubitemid 32600131)
56. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H (1998) Coexistence of Alzheimer-type Neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol 96, 116-122. (Pubitemid 28356523)
57. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, Soto C (2010) Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci 30, 4528-4535.
58. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541, 163-166.
59. Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, Glatzel M (2008) Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis 5, 347-354.
60. Van Everbroeck B, Green AJ, Pals P, Martin JJ, Cras P (1999) Decreased Levels of Amyloid-beta 1-42 in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients. J Alzheimers Dis 1, 419-424.